Goldman Sachs Initiates Coverage On Tandem Diabetes Care with Neutral Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Tandem Diabetes Care with a Neutral rating and set a price target of $46.
October 04, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has initiated coverage on Tandem Diabetes Care with a Neutral rating and a price target of $46, indicating a balanced view on the stock's potential.
The Neutral rating suggests that Goldman Sachs sees neither significant upside nor downside in the short term for Tandem Diabetes Care. The price target of $46 provides a benchmark for investors, but the neutral stance indicates a balanced view on the stock's potential movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100